Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 30;13(1):21.
doi: 10.1038/s41408-023-00786-x.

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

Paola Guglielmelli #  1 , Chiara Maccari #  1 , Benedetta Sordi  1 , Manjola Balliu  1 , Alessandro Atanasio  1 , Carmela Mannarelli  1 , Giulio Capecchi  1 , Ilaria Sestini  1 , Giacomo Coltro  1 , Giuseppe Gaetano Loscocco  1   2 , Giada Rotunno  1 , Eva Angori  3 , Filippo C Borri  3 , Ayalew Tefferi #  4 , Alessandro M Vannucchi #  5
Affiliations

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

Paola Guglielmelli et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

AMV and PG reports participation to advisory boards and lecture fees from Novartis.

Figures

Fig. 1
Fig. 1. Impact of CALR mutation variant allele frequency on outcomes in myelofibrosis.
Kaplan–Meier analysis of Overall Survival (panel A), Leukemia-free Survival (panel B), Anemia-free Survival (panel C) and Leukocytosis-free Survival (panel D) in CALR-mutated patients according to their high and low variant allele frequency burden. Please refer to text for definitions and details. HR 95% CI, hazard ratio, 95% confidence Interval.
See this image and copyright information in PMC

References

    1. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405. doi: 10.1056/NEJMoa1312542. - DOI - PMC - PubMed
    1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90. doi: 10.1056/NEJMoa1311347. - DOI - PubMed
    1. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96:145–62. doi: 10.1002/ajh.26050. - DOI - PubMed
    1. Stengel A, Jeromin S, Haferlach T, Meggendorfer M, Kern W, Haferlach C. Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease. Haematologica. 2019;104:e187–e90.. doi: 10.3324/haematol.2018.202952. - DOI - PMC - PubMed
    1. Theocharides APA, Lundberg P, Lakkaraju AKK, Lysenko V, Myburgh R, Aguzzi A, et al. Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood. 2016;127:3253–9. doi: 10.1182/blood-2016-02-696310. - DOI - PubMed

Publication types